Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

AIM ImmunoTech Inc. (AIM) vs CollPlant Biotechnologies Ltd. Sponsored ADR (CLGN)

AIM ImmunoTech Inc. and CollPlant Biotechnologies Ltd. Sponsored ADR are both Biotechnology companies. AIM ImmunoTech Inc. and CollPlant Biotechnologies Ltd. Sponsored ADR are of similar size ($8.0M and $7.8M). AIM ImmunoTech Inc. grew revenue faster over the last twelve months: −21.5% against −84.3%. CollPlant Biotechnologies Ltd. Sponsored ADR has the higher net margin (−3,376.4% vs −15,021.1%) and the lower return on invested capital (−3,125.0% vs 0.00%). Across the 17 metrics below, CollPlant Biotechnologies Ltd. Sponsored ADR leads on 9 and AIM ImmunoTech Inc. on 8.

Valuation

Metric AIM CLGN Biotechnology median
P/E n/m n/m 7.88
P/S 34.24 15.02 11.47
P/B 0.42 1.20 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.65 n/m 0.74
EV/Sales (66.26) 11.73 10.73
Earnings yield (1,537.53%) (244.30%) (28.84%)
Free cash flow yield (449.55%) (194.58%) (23.03%)

Profitability

Metric AIM CLGN Biotechnology median
Gross margin (23.16%) (147.56%) 65.16%
Operating margin (11,724.21%) (3,329.05%) 0.00%
Net margin (15,021.05%) (3,376.35%) 0.00%
Free cash flow margin (15,385.26%) (2,911.57%) 0.00%
Return on equity (2,382.30%) (151.99%) (57.72%)
Return on assets (169.28%) (99.53%) (49.22%)
Return on invested capital 0.00% (3,125.00%) 0.00%

Growth

Metric AIM CLGN Biotechnology median
Revenue growth (TTM) (21.49%) (84.26%) 5.64%
EPS growth (last fiscal year) 72.19% 35.17% —
Revenue growth, 5-year CAGR (11.60%) (17.32%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM CLGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.11 2.27 4.73
Net debt to EBITDA 0.22 0.56 0.96

Dividend

Metric AIM CLGN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric AIM CLGN Biotechnology median
Market cap 7.97m 7.79m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack